Results for efficacy end-points
| End-point | Placebo | Montelukast | Beclomethasone |
| Asthma control days % | 40.0±35.8 | 50.7±37.1# | 57.9±36.1*,¶ |
| FEV1 % change from baseline | 6.4±20.1 | 12.1±18.7# | 13.9±20.8¶ |
| Daily β‐agonist use % change from baseline | −15.7±50.0 | −35.7±42.6# | −45.7±41.6*,¶ |
| Patient global evaluation | 1.5±1.53 | 1.1±1.19# | 0.9±1.00*,¶ |
| Physician global evaluation | 1.9±1.47 | 1.3±1.20# | 1.2±1.08¶ |
| Asthma attack % patients+ | 14.9±35.1 | 5.5±22.8# | 3.9±19.3¶ |
Data are presented as mean±sd
FEV1: forced expiratory volume in one second
*: p<0.05 for montelukast-beclomethasone comparison
#: p<0.05 for placebo-montelukast comparison
¶: p<0.05 for placebo-beclomethasone comparison
+: n values for placebo, montelukast and beclomethasone were 101, 308 and 308, respectively